SemBioSys announces second quarter 2008 financial and operational results



    Canadian Biotechnology Company hits key insulin and Apo AI(Milano)
    milestones

    TSX symbol: SBS

    CALGARY, Aug. 5 /CNW/ - SemBioSys Genetics Inc. (TSX:SBS), a
biotechnology company developing a portfolio of therapeutic proteins for
metabolic and cardiovascular diseases, today announced its 2008 second quarter
financial and operational results.

    
    Highlights

    Insulin Program

    -   Submitted an Investigational New Drug Application (IND) for
        safflower-produced insulin to the U.S. Food and Drug Administration
        (FDA), subsequent to the end of the quarter.
    -   Met with the European Medicines Agency (EMEA) to agree upon a
        clinical development strategy designed to allow simultaneous European
        and U.S. submissions for safflower-produced insulin.

    Apo AI Program

    -   Demonstrated that safflower-produced Apo AI(Milano) is functional, by
        measuring increased cholesterol mobilization, in a widely accepted
        animal model.

    Botaneco

    -   Received $4 million in funding from Avrio Ventures Limited
        Partnership in the form of a convertible debenture to accelerate the
        commercialization of Hydresia(TM) products from Botaneco Specialty
        Ingredients Inc., a SemBioSys subsidiary.
    

    Outlook

    SemBioSys intends to follow its recent IND application with the
submission of a Clinical Trial Application (CTA) to the appropriate European
authorities later in the third quarter of this year. In order to meet both FDA
and EMEA requirements, the Company plans to conduct a Phase I/II clinical
trial wherein safflower-produced insulin is compared to both U.S. and
European-sourced reference insulin. The upcoming insulin milestone events
include:

    
    -   Complete production of clinical grade insulin supply for use in Phase
        I/II human clinical trials.
    -   Upon CTA approval, initiation of a single-dose Phase I/II clinical
        trial of safflower-produced insulin in the United Kingdom in the
        fourth quarter of 2008.
    -   Continuation of business development activities toward an insulin
        partnership.
    

    In 2007, SemBioSys successfully achieved commercial levels of both Apo AI
and Apo AI(Milano) accumulation in safflower. With positive results
demonstrating safflower-produced Apo AI(Milano) increased cholesterol
mobilization in animals earlier this year, SemBioSys is continuing testing in
animals to establish that safflower-produced Apo AI(Milano) is equivalent to
microbial-produced Apo AI(Milano) with respect to plaque-remodeling and plaque
regression. The upcoming milestone events include:

    
    -   Completion of in vivo efficacy studies of plaque remodeling with
        safflower-produced Apo AI(Milano) followed by studies of plaque
        regression using a mouse model.
    -   Continuation of the formal partnering process for safflower-produced
        Apo AI(Milano). The Company has already initiated confidential
        discussions with several potential large pharmaceutical partners.
    

    In addition to its pharmaceutical milestones, SemBioSys also expects to
collect milestone payments from Arcadia Biosciences, Inc., upon their
successful commercial scale-up and market launch of High GLA Safflower Oil in
late 2008 or early 2009.
    Meanwhile, Botaneco is also advancing the development of its personal
care ingredient products with the expansion of the commercial distribution of
Hydresia(TM) and Hydresia(TM) G2. With the completion of the recent funding
transaction with Avrio, along with the previously committed $2.4 million from
AVAC Ltd., SemBioSys expects Botaneco to be self-financing moving forward.
    "The progress we have made with our two lead pharmaceutical programs,
insulin and Apo AI(Milano), over the past few months has transformed
SemBioSys. We are now poised to have insulin enter the clinic later this year
as the first recombinant human protein produced from safflower to advance into
human trials, which addresses a component of the largest volume drug protein
market in the world. The animal results we received demonstrating
safflower-produced Apo AI(Milano) successfully increased cholesterol
mobilization were a critical milestone for the Company. With these data in
hand, we are now able to intensify our formal partnering process for Apo
AI(Milano) in parallel to the execution of additional animal studies designed
to show plaque remodeling and plaque regression. We are already engaged in
discussions with several major pharmaceutical companies concerning this
program," said Andrew Baum, president and chief executive officer of
SemBioSys. "As we advanced each of our pharmaceutical programs we also made
important operational progress with our subsidiary, Botaneco. The funding from
AVAC and Avrio provides Botaneco with the financial independence to pursue
commercial opportunities on its own, while SemBioSys focuses its resources on
advancing the insulin and Apo AI(Milano) programs."

    Financials

    Prior to the third quarter of 2007, SemBioSys operated under one segment.
During the third quarter of 2007, Botaneco completed construction of its
manufacturing facility and SemBioSys began to operate in two reportable
segments: (i) the Biopharmaceutical, Animal Health and Nutritional Oils
segment focused on the Company's lead pharmaceutical candidates, recombinant
human insulin and Apo AI(Milano) and (ii) the Specialty Ingredients segment.
As of October 1, 2007, Botaneco Specialty Ingredients Inc. was established as
a separate legal entity, and SemBioSys' previously dormant U.S. subsidiary,
SemBioSys Inc., was renamed as Botaneco Inc.
    Total revenue for the three and six-month periods ended June 30, 2008 was
$62,207 and $272,234 respectively, compared with $459,407 and $1,002,195 for
the corresponding periods in 2007. The difference is due mainly to a license
fee payment earned from the Company's collaboration agreement with Martek
BioSciences Corporation in the first half of 2007 which is partially offset by
2008 product sales revenue from Hydresia(TM) and the option payment received
from INDEAR S.A.
    Total expenditures for the three and six-month periods ended June 30,
2008 were $6,542,258 and $11,799,869 respectively, compared with $4,046,723
and $7,990,131 for the corresponding periods last year.
    Research and development expenses for the three and six-month periods
ended June 30, 2008 were $3,357,683 and $6,151,786, compared with $1,924,745
and $3,668,717 for the corresponding periods last year. The difference is
primarily related to the shift in the stage of development of the Company from
research to preclinical development of two major drug candidates, which
requires significant external resources to advance and prepare for the
upcoming clinical trials. These include increased contract research
organization (CRO) costs, independent third party animal studies, preparation
of GMP and cGMP material and other outsourcing costs, as well as increased
personnel and the associated support costs and laboratory supplies related to
preclinical activity.
    General and administrative expenses for the three and six-month periods
ended June 30, 2008 were $1,666,323 and $3,061,598 respectively, compared with
$1,086,766 and $2,110,477 for the corresponding periods last year. The
difference is mainly due to the commercial operations of Botaneco being fully
established during 2008 resulting in additional increases in general and
administrative costs and legal fees incurred for the Botaneco debenture
financing.
    Intellectual property costs for the three and six-month periods ended
June 30, 2008 were $504,690 and $847,020 respectively, compared with $307,414
and $835,663 for the corresponding periods last year. The difference in costs
for the three-month periods is due mainly to an increase in legal costs for
patent applications for the Company's insulin program during 2008, which were
partially offset by a decrease in royalty payments.
    Business development costs for the three and six-month periods ended
June 30, 2008 were $155,522 and $315,152 respectively, compared with $404,434
and $713,909 for the corresponding periods last year. The difference is
primarily due to the shift in Botaneco's activities from essentially entirely
business development related prior to the commissioning of its commercial
manufacturing operations which occurred in September 2007, to now being fully
operational.
    Net loss for the 2008 second quarter was $6,414,856 or ($0.25) per share,
compared to a net loss of $3,225,371 or ($0.15) per share for the same period
last year. Net loss for the six-month period ended June 30, 2008 was
$11,431,911 or ($0.44) per share compared with $6,453,782 or ($0.31) per share
for the same six-month period last year. The change in net loss is primarily
due to the increased commercial activities of Botaneco and the increased
preclinical activities related to insulin and Apo AI.
    As at June 30, 2008 the Company had cash and cash equivalents totaling
$14,101,923 and a net positive working capital balance of $13,154,749 compared
to $20,444,013 and $19,518,408 respectively, at December 31, 2007. Total
long-term debt and convertible debentures at June 30, 2008 was $4,352,904
compared with $1,389,047 at December 31, 2007.
    As at July 31, 2008 the Company had 25,938,294 common shares outstanding,
2,390,000 warrants and 2,387,269 options.

    About SemBioSys Genetics Inc. (www.sembiosys.com)

    Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company
developing protein-based pharmaceuticals for metabolic and cardiovascular
diseases. The Company's lead pharmaceutical candidates, produced in the plant
host safflower, are recombinant human insulin to serve the rapidly expanding
global diabetes market and Apo AI(Milano), a next generation cardiovascular
drug. In addition to its pharmaceutical products, SemBioSys and its
subsidiary, Botaneco Specialty Ingredients Inc., are developing a series of
non-pharmaceutical products addressing human topical, nutritional oils and
agricultural biotechnology markets. More information is available and can be
accessed at www.sembiosys.com.

    This press release contains certain forward-looking statements,
including, without limitation, statements containing the words "believe",
"may", "plan", "will", "estimate", "continue", "anticipate", "intend",
"expect" and other similar expressions which constitute "forward-looking
information" within the meaning of applicable Canadian securities laws.
Forward-looking statements reflect the Company's current expectation and
assumptions, and are subject to a number of risks and uncertainties that could
cause actual results to differ materially from those anticipated. These
forward-looking statements involve risks and uncertainties including, but not
limited to, changing market conditions, the successful and timely completion
of clinical studies, the establishment of corporate alliances, the impact of
competitive products and pricing, new product development, uncertainties
related to the regulatory approval process and other risks detailed from
time-to-time in the Company's ongoing filings with the Canadian securities
regulatory authorities which filings can be found at www.sedar.com. Given
these risks and uncertainties, readers are cautioned not to place undue
reliance on such forward-looking statements. The Company undertakes no
obligation to publicly update or revise any forward-looking statements either
as a result of new information, future events or otherwise, except as required
by applicable Canadian securities laws.

    Financials results included below:

    
    SemBioSys Genetics Inc.
    Consolidated Balance Sheets
    (Unaudited)
    -------------------------------------------------------------------------
    (expressed in Canadian dollars)

                                                        June 30, December 31,
                                                           2008         2007
                                                              $            $
                                                    ------------ ------------
    Assets
    Current assets
    Cash and cash equivalents                        14,101,923   20,444,013
    Accounts receivable                                 228,300      613,912
    Prepaid expenses and deposits                       317,810      538,718
    Inventory                                           743,568      426,641
                                                    ------------ ------------
                                                     15,391,601   22,023,284

    Property and equipment                            8,969,956    9,272,415
                                                    ------------ ------------

                                                     24,361,557   31,295,699
                                                    ------------ ------------
                                                    ------------ ------------

    Liabilities
    Current liabilities
    Accounts payable and accrued liabilities          1,673,651    1,875,397
    Short-term portion of long-term debt                563,201      629,479
                                                    ------------ ------------
                                                      2,236,852    2,504,876

    Deferred cost recoveries                            207,527      286,596

    Long-term debt                                    1,216,830      759,568

    Convertible debenture                             2,572,873            -
                                                    ------------ ------------
                                                      6,234,082    3,551,040
                                                    ------------ ------------
                                                    ------------ ------------

    Shareholders' Equity
    Capital stock                                    70,427,920   70,396,170

    Warrants                                          2,550,880    6,180,690

    Contributed surplus                              11,312,622    7,326,962

    Equity component of convertible debenture         1,427,127            -

    Deficit                                         (67,591,074) (56,159,163)
                                                    ------------ ------------
                                                     18,127,475   27,744,659
                                                    ------------ ------------

                                                     24,361,557   31,295,699
                                                    ------------ ------------
                                                    ------------ ------------



    SemBioSys Genetics Inc.
    Consolidated Statements of Loss, Comprehensive Loss and Deficit
    (Unaudited)
    -------------------------------------------------------------------------
    (expressed in Canadian dollars, except shares)

                          Three month period ended    Six month period ended
                              June 30,     June 30,     June 30,     June 30,
                                 2008         2007         2008         2007
                          ------------ ------------ ------------ ------------
                                    $            $            $            $

    Revenue
    Licensing fees                  -      437,012       50,110      874,024
    Contract research               -       22,395            -      128,171
    Product sales              62,207            -      222,124            -
                          ------------ ------------ ------------ ------------
                               62,207      459,407      272,234    1,002,195

    Expenses
    Research and
     development            3,357,683    1,924,745    6,151,786    3,668,717
    General and
     administration         1,666,323    1,086,766    3,061,598    2,110,477
    Intellectual property
     costs                    504,690      307,414      847,020      835,663
    Business development      155,522      404,434      315,152      713,909
    Sales and marketing        96,621            -      249,781            -
    Cost of products sold      45,534            -      317,279            -
    Stock-based
     compensation             175,947      186,654      355,850      365,704
    Amortization              580,733      241,887    1,074,567      469,945
    Cost recoveries           (40,795)    (105,177)    (573,164)    (174,284)
                          ------------ ------------ ------------ ------------
                            6,542,258    4,046,723   11,799,869    7,990,131
                          ------------ ------------ ------------ ------------

    Loss before the
     undernoted            (6,480,051)  (3,587,316) (11,527,635)  (6,987,936)
                          ------------ ------------ ------------ ------------
                          ------------ ------------ ------------ ------------

    Interest income            96,649      262,962      267,507      475,195
    Interest expense          (43,412)     (52,570)    (105,076)    (110,543)
    Loss on sale of
     property and
     equipment                      -       (1,483)           -       (1,483)
    Foreign exchange
     gain (loss)               11,958      153,036      (66,707)     170,985
                          ------------ ------------ ------------ ------------
                          ------------ ------------ ------------ ------------

                               65,195      361,945       95,724      534,154
                          ------------ ------------ ------------ ------------

    Net loss and
     comprehensive loss
     for the period        (6,414,856)  (3,225,371) (11,431,911)  (6,453,782)

    Deficit - Beginning
     of period            (61,176,218) (43,968,897) (56,159,163) (40,740,486)
                          ------------ ------------ ------------ ------------
                          ------------ ------------ ------------ ------------

    Deficit - End of
     period               (67,591,074) (47,194,268) (67,591,074) (47,194,268)
                          ------------ ------------ ------------ ------------
                          ------------ ------------ ------------ ------------

    Loss per share -
     basic and diluted          (0.25)       (0.15)       (0.44)       (0.31)
                          ------------ ------------ ------------ ------------
                          ------------ ------------ ------------ ------------

    Weighted average
     shares outstanding    25,937,476   22,089,356   25,936,634   20,511,557
                          ------------ ------------ ------------ ------------
                          ------------ ------------ ------------ ------------



    SemBioSys Genetics Inc.
    Consolidated Statements of Cash Flows
    (Unaudited)
    -------------------------------------------------------------------------
    (expressed in Canadian dollars)

                          Three month period ended    Six month period ended
                              June 30,     June 30,     June 30,     June 30,
                                 2008         2007         2008         2007
                          ------------ ------------ ------------ ------------
                                    $            $            $            $

    Cash provided by
     (used in)
    Operating activities
    Net loss for the
     period                (6,414,856)  (3,225,371) (11,431,911)  (6,453,782)
    Add items not
     affecting cash:
      Amortization            580,733      241,887    1,074,567      469,945
      Loss on sale of
       property and
       equipment                    -        1,483            -        1,483
      Stock-based
       compensation           175,947      186,654      355,850      365,704
      Unrealized foreign
       exchange loss (gain)     4,991     (128,534)      49,002     (149,544)
      Non-cash interest
       expense                 18,288            -       37,068            -
                          ------------ ------------ ------------ ------------
                           (5,634,897)  (2,923,881)  (9,915,424)  (5,766,194)
                          ------------ ------------ ------------ ------------
                          ------------ ------------ ------------ ------------

    Change in non-cash
     working capital and
     other balances
     related to
     operations                88,886     (686,470)     298,802      795,297
                          ------------ ------------ ------------ ------------

    Cash used in operating
     activities            (5,546,011)  (3,610,351)  (9,616,622)  (4,970,897)
                          ------------ ------------ ------------ ------------
                          ------------ ------------ ------------ ------------

    Financing activities
    Issuance of capital
     stock                          -            -            -   15,904,488
    Share issue costs               -     (168,939)     (57,884)  (1,525,478)
    Issuance of
     convertible debenture  4,000,000            -    4,000,000            -
    Exercise of stock
     options                        -       10,000       31,750       14,500
    Repayment of
     long-term debt          (158,038)    (191,843)    (310,584)    (375,812)
    Proceeds from
     long-term debt                 -            -      634,900            -
    Repayment of
     repayable advances             -            -            -      (85,640)
                          ------------ ------------ ------------ ------------

    Cash provided by
     (used in) financing
     activities             3,841,962     (350,782)   4,298,182   13,932,058
                          ------------ ------------ ------------ ------------
                          ------------ ------------ ------------ ------------

    Investing activities
    Proceeds on sale of
     property and
     equipment                      -        6,000            -        6,000
    Acquisition of
     property and
     equipment               (478,806)  (1,973,020)  (1,023,650)  (2,417,836)
                          ------------ ------------ ------------ ------------

    Cash used in
     investing activities    (478,806)  (1,967,020)  (1,023,650)  (2,411,836)
                          ------------ ------------ ------------ ------------
                          ------------ ------------ ------------ ------------

    Increase (decrease)
     in cash and cash
     equivalents           (2,182,855)  (5,928,153)  (6,342,090)   6,549,325

    Cash and cash
     equivalents -
     Beginning of period   16,284,778   28,805,937   20,444,013   16,328,459
                          ------------ ------------ ------------ ------------
                          ------------ ------------ ------------ ------------

    Cash and cash
     equivalents - End
     of period             14,101,923   22,877,784   14,101,923   22,877,784
                          ------------ ------------ ------------ ------------
                          ------------ ------------ ------------ ------------

    Supplemental
     Information
    Cash interest
     received                 224,636      308,755      325,244      912,394
    Cash interest paid         25,123       47,864       53,878       99,206
    Non-cash transactions
      Capital items
       included in
       accounts payable        24,831      824,063       24,831      824,063
                          ------------ ------------ ------------ ------------
                          ------------ ------------ ------------ ------------
    





For further information:

For further information: SemBioSys Genetics Inc., Mr. Andrew Baum,
President and Chief Executive Officer, Phone: (403) 717-8767, Fax: (403)
250-3886, E-mail: bauma@sembiosys.com, Internet: www.sembiosys.com; The Trout
Group, Ian Clements, Senior Vice President, Phone: (415) 392-3385, E-mail:
iclements@troutgroup.com

Organization Profile

SemBioSys Genetics Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890